LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Home・Aandelen Lijst・BioNTech SE ADR

BioNTech SE ADR

Gesloten

SectorGezondheidszorg

97.13 4.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

92.75

Max

97.35

Belangrijke statistieken
By Trading Economics
Inkomsten	143M 301M
Verkoop	-55M 1.2B
EPS	-1.821
Winstmarge	25.311
Werknemers	6,772
EBITDA	253M 464M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+51.45% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-852M 25B
Vorige openingsprijs	92.41
Vorige sluitingsprijs	97.13

Nieuwssentiment

By Acuity

72%

28%

349 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

92.4 / 103.5 Steun & Weerstand

BioNTech SE ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 18:52 UTC

Belangrijke Marktbewegers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov 2024, 10:28 UTC

Belangrijke Marktbewegers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

5 mei 2025, 15:13 UTC

Marktinformatie

Winsten

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 nov 2024, 11:14 UTC

Marktinformatie

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov 2024, 10:34 UTC

Marktinformatie

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 aug 2024, 10:02 UTC

Winsten

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 aug 2024, 10:01 UTC

Winsten

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 aug 2024, 10:01 UTC

Winsten

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 aug 2024, 10:00 UTC

Winsten

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Loss EUR807.8M >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Rev EUR128.7M >BNTX

Peer Vergelijking

Prijswijziging

BioNTech SE ADR Prognose

Koersdoel

By TipRanks

51.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 140.5 USD 51.45%

Hoogste 171 USD

Laagste 110 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioNTech SE ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Gebaseerd op 18 analisten die aandelenratings hebben gegeven aan BioNTech SE ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

92.4 / 103.5Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

349 / 382 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac